Accelerated Approval Roadblock: Agenus’ PD-1 Stumble Reflects Pathway’s Regulatory Risk

 
• By Sue Sutter and Bridget Silverman
Roadblock
Balstilimab's road to accelerated approval was blocked by Keytruda's conversion to regular approval in second-line cervical cancer. • Source: Alamy

More from Review Pathways

More from Pathways & Standards